Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P de Souza

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Science Translational Medicine|March 29, 2013
Protein replacement therapies for rare diseases: a breeze for regulatory approval?Jennifer A Gorzelany, Mark P de Souza
The Journal of Investigative Dermatology|January 18, 2013
Response to Horn et alMark P de Souza, Vanessa Rangel Miller
The Journal of Investigative Dermatology|June 15, 2012
Significance of patient registries for dermatological disordersMark P de Souza, Vanessa Rangel Miller
Cancers|February 24, 2024
Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)Stuart L Marcus, Mark P de Souza
Plant Physiology|February 14, 2002
Selenium assimilation and volatilization from selenocyanate-treated Indian mustard and muskgrassMark P de Souza, Ingrid J Pickering, Michael Walla, et al.
Pediatric Dermatology|September 8, 2020
Financial burden of epidermolysis bullosa on patients in the United StatesEmily S Gorell, Paige W Wolstencroft, Mark P de Souza, et al.
The Journal of Investigative Dermatology|October 4, 2021
Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis BullosaChristine Gretzmeier, Didier Pin, Johannes S Kern, et al.
Journal of the American Academy of Dermatology|March 23, 2020
Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional surveyVictor A Eng, Daniel C Solis, Emily S Gorell, et al.
Molecular Therapy. Advances|May 18, 2026
Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosaChristine Gretzmeier, Bing Hang, Gerhard Sengle, et al.
Orphanet Journal of Rare Diseases|July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplexJodi Y So, Shivali Fulchand, Christine Y Wong, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Science Translational Medicine|March 29, 2013
Protein replacement therapies for rare diseases: a breeze for regulatory approval?Jennifer A Gorzelany, Mark P de Souza
The Journal of Investigative Dermatology|January 18, 2013
Response to Horn et alMark P de Souza, Vanessa Rangel Miller
The Journal of Investigative Dermatology|June 15, 2012
Significance of patient registries for dermatological disordersMark P de Souza, Vanessa Rangel Miller
Cancers|February 24, 2024
Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)Stuart L Marcus, Mark P de Souza
Plant Physiology|February 14, 2002
Selenium assimilation and volatilization from selenocyanate-treated Indian mustard and muskgrassMark P de Souza, Ingrid J Pickering, Michael Walla, et al.
Pediatric Dermatology|September 8, 2020
Financial burden of epidermolysis bullosa on patients in the United StatesEmily S Gorell, Paige W Wolstencroft, Mark P de Souza, et al.
The Journal of Investigative Dermatology|October 4, 2021
Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis BullosaChristine Gretzmeier, Didier Pin, Johannes S Kern, et al.
Journal of the American Academy of Dermatology|March 23, 2020
Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional surveyVictor A Eng, Daniel C Solis, Emily S Gorell, et al.
Molecular Therapy. Advances|May 18, 2026
Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosaChristine Gretzmeier, Bing Hang, Gerhard Sengle, et al.
Orphanet Journal of Rare Diseases|July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplexJodi Y So, Shivali Fulchand, Christine Y Wong, et al.
Pageof 2